The relationship between magnesium levels and mortality in the respiratory intensive care unit

Mustafa Özgür Çirk, MD⁵, Mukaddes Kılç, MD⁵, Guler Eraslan Doğanay, MD⁵, Meriç Ünver, MD⁵, Murat Yıldız, MD⁵, Sema Avcı, MD⁵,∗

Abstract
Magnesium deficiency is defined as a pathophysiologic factor in numerous illnesses. This study aims to define the effects of magnesium levels on patients in the intensive care unit (ICU) regarding length of stay in the ICU, length of mechanical ventilation (MV), and 28-day mortality.

The following data were collected during initial assessment of patients admitted to the ICU with acute respiratory failure (ARF). Demographic data, magnesium and potassium levels, Charlson’s Comorbidity Index (CCI), Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores, length of MV, length of hospital stay in the ICU, 28-day mortality, and ICU discharge status.

In the initial serum analysis prior to treatment of patients in the ICU, the mortality rate of the patient group with hypermagnesemia was found to be statistically significant when compared with other magnesium levels (P = .018). Apart from renal failure, ICU mortality is higher in the hypermagnesemia group than other groups.

Hypermagnesemia is an electrolyte abnormality that is generally seen in older individuals and those with serious comorbidity and it can be used in mortality prediction.

Abbreviation: CCI = Charlson’s Comorbidity Index, APACHE II = Acute Physiology and Chronic Health Evaluation, SOFA = Sequential Organ Failure Assessment, COPD = Chronic obstructive pulmonary disease.

Keywords: acute respiratory failure, hypermagnesemia, intensive care unit, magnesium level, mortality

Learning points
• Hypomagnesemia has been associated with ICU mortality in numerous studies.
• However, hypermagnesemia, an electrolyte abnormality generally seen in older patients and those with serious comorbidity, is also associated with mortality.
• Hypermagnesemia is a result of the cell lysis process and can be used as a parameter in predicting mortality.

1. Introduction
Magnesium is the fourth most common electrolyte in the human body and has a role as a cofactor in nucleic acid synthesis, particularly in adenosine triphosphate as well as in enabling nerve conduction, insulin metabolism, protein synthesis, cardiac muscle contraction, bronchodilatation, the functioning of the autonomic nervous system, and more than 300 biochemical reactions in the body.[1,2] Magnesium deficiency has been found to cause an increase in systemic inflammatory response which is one of the agents in the pathophysiology of numerous illnesses.[1,2] Although magnesium levels play an important role in the process of illnesses it has not been routinely monitored in clinical practice. This lack of attention is defined as “the Forgotten Electrolyte” by some authors.[3,4]

Numerous research studies have been conducted on the negative impact of high hypomagnesemia incidence rates in patients treated in the ICU, such as increased mortality, need for prolonged mechanical ventilation (MV) and increased stay in the ICU. Even with these negative effects of hypomagnesemia, there is not sufficient evidence on the beneficial effects of magnesium replacement for patients with hypomagnesemia.[2,5]

This study aims to evaluate the effect of magnesium levels, measured initially on admission of patients to the ICU due to ARF, on the length of MV, length of stay in the ICU, and mortality. Moreover, since the majority of the participants were diagnosed with COPD (chronic obstructive pulmonary disease), the relationship between the existence of COPD and magnesium levels was also evaluated.

2. Methods
Ethical approval for this cross-sectional study was obtained (05.30.2019/630) from Health Sciences University Ankara

© The Author(s). Published by Wolters Kluwer Health, Inc.
DOI: 10.1097/MD.0000000000023290
http://dx.doi.org/10.1097/MD.0000000000023290
Atatürk Education and Research Hospital, and 351 patients, who were 18 years and older and admitted to the ICU in 2018 with a diagnosis of COPD, were evaluated. The magnesium and potassium values of 20 patients could not be obtained and 2 patients died within 24 hours after hospitalization. These patients were excluded from the study. Therefore, the data of 329 patients were analyzed (Flowchart, http://links.lww.com/MD/F323).

The data were obtained from the hospital registration system and consisted of information regarding age, gender, existence of COPD, length of hospital stay and time in the ICU, magnesium and potassium levels, Charlson’s Comorbidity Index (CCI), Acute Physiology and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA) score, length of MV, 28-day mortality, and ICU discharge status. Additionally, the patients were categorized in the following groups according to their serum magnesium levels: hypomagnesemia (below 1.8 mg/dl), normomagnesemia (1.8–2.6 mg/dl), and hypermagnesemia (over 2.6 mg/dl). Patients were additionally categorized according to the existence of COPD. The serum electrolyte analyses were carried out in the biochemistry laboratory of the hospital in which this study was conducted using the Beckman Coulter AU 5800 (Beckman Coulter, Inc. CA, US).

2.1. Statistical analysis

Data were analyzed using the SPSS 21.0 software package. Continuous variables were defined as mean ± standard deviation, and the categorical variables as number and percentage. The differences between categorical variables were analyzed with the Chi-Squared analysis. The distribution of the variables were measured with the Kolmogorov Smirnow test. The Mann–Whitney U and Kruskal–Wallis tests were used in the analysis of quantitative independent data. The prediction success of the mortality prediction scores were evaluated using the ROC analysis. In the analyses, \( P < .05 \) was accepted as statistically significant.

3. Results

Of the participants, 203 were male (61.7%) and 126 were female (38.3%). The mean age was found to be 70.27 ± 13.33 years. Since this study was conducted in a pulmonology hospital, the

**Table 1**

| Patient age, gender, existence of COPD, and magnesium levels. | Mean ± sd | Percentage (%) |
|---------------------------------------------------------------|-----------|----------------|
| Age                                                           | 70.27 ±13.3 | - |
| Gender (F/M)                                                  | 126/203   | 38.3/61.7 |
| COPD (+/-)                                                    | 222/107   | 67.5/32.5 |
| Magnesium level (mg/dL)                                       |           |              |
| Hypomagnesemia                                               | 85        | 25.8         |
| Normomagnesemia                                              | 219       | 66.6         |
| Hypermagnesemia                                              | 25        | 7.6          |

COPD = Chronic Obstructive Pulmonary Disease, F = female, M = male, age mean ± standard deviation, gender, existence of COPD, and magnesium levels were defined as number and percentage.
The patients were categorized according to their magnesium levels as hypomagnesemia, normomagnesemia, and hypermagnesemia; no statistically significant difference was found between these groups in terms of COPD and 28-day mortality (Table 5). ICU mortality was found to be significantly higher in the hypermagnesemia group than the other groups (P = .018).

No statistical significance was found between magnesium levels and the length of hospital stay, length of stay in the ICU, length of MV, and potassium values (Table 6). In the comparison of APACHE II, SOFA, and CCI scores in terms of magnesium levels, SOFA and CCI scores were found to be significantly higher in the hypermagnesemia group (SOFA; CCI P < .01). All mean mortality prediction scores of the hypermagnesemia group (APACHE II, SOFA, CCI) were above the cut-off values according to the ROC curve analysis (Table 7).

Mg2+ levels of the seven patients who received continuous renal replacement therapy (CRRT) were evaluated and it was found that six of those patients were normomagnesemic and only 1 of them was hypomagnesemic. None of the patients with hypermagnesemia needed CRRT.

In the comparison of the magnesium levels of the patients who received MV, it was found that the majority of those patients were normomagnesemic (n = 101, 67.3%); and no statistical significant relationship was found between the need for MV and magnesium levels (P = .082).

4. Discussion

This study, which evaluated the effect of magnesium levels of patients in the ICU due to ARF on 28-day mortality, length of hospital stay and stay in the ICU, and length of MV, showed that hypomagnesemia and normomagnesemia did not have an impact on these results. Additionally, patients diagnosed with hypermagnesemia had higher mortality rates during the ICU follow-up process than the other groups. In this study, which mostly
included COPD patients, the analysis of the COPD subgroup showed there was no difference in terms of 28-day mortality, length of stay in the ICU, and length of MV in this subgroup. Moreover, APACHE II and SOFA scores and CCI were found to be effective in predicting mortality.

There are numerous studies showing that lower magnesium levels in serum can be associated with chronic inflammatory stress and have an impact on mortality.\(^{[6-9]}\) However, there are also studies that show that hypermagnesemia is associated with mortality but lower magnesium levels are not.\(^{[5,10]}\)

The relationship between coronary failure and magnesium levels are a popular subject among researchers. Teeranan et al have conducted a metanalysis which included studies evaluating the relationship between magnesium levels and mortality of patients diagnosed with coronary failure.\(^{[11]}\) They found that a hypermagnesemic (Mg ≥ 1.05 mmol/L (2.5mg/dl)) patient group who presented with coronary failure was found to have higher rates of cardiovascular mortality. This result shows that the relationship between cardiac function disorder, which is commonly observed in critical patients group, and magnesium is significant. Guerin et al have investigated the relationship between hypermagnesemia and mortality in their study which included different illness groups in the general ICU.\(^{[11]}\) Although in this study the number of patients in the hypermagnesemia

### Table 4

The relationship between the existence of COPD and length of hospital stay, length of stay in the ICU, and length of MV.

| COPD (+) | COPD (-) |
|---------|---------|
| mean ± sd | median | mean ± sd | median | \(P\) value\(^{**}\) |
| Age     | 70.62 ± 11.4 | 70 | 69.54 ± 16.5 | 73 | .616 |
| APACHE II | 21.39 ± 6.60 | 20 | 24.21 ± 7.60 | 29 | .001 |
| SOFA    | 6.28 ± 1.94  | 6  | 7.30 ± 2.80  | 7  | .003 |
| CCI     | 5.73 ± 1.9   | 6  | 6.51 ± 2.6   | 6  | .012 |
| Length of hospital stay (days) | 19.35 ± 15.9 | 15 | 18.07 ± 15.3 | 14 | .271 |
| Length of stay in the ICU (days) | 5.58 ± 4.50 | 3 | 6.02 ± 4.82 | 4 | .706 |
| Length of MV follow-up\(^{*}\) (n=149) (days) | 7.57 ± 9.5 (n=84) | 3 | 6.22 ± 7.48 (n=65) | 3 | .291 |
| Magnesium (mg/dL) | 1.9 ± 0.49 | 1.9 | 2.01 ± 0.47 | 1.9 | .718 |
| Potassium (mEq/L) | 4.4 ± 0.80 | 4.4 | 4.20 ± 0.90 | 4.3 | .147 |

\(APACHE\ II = \text{Chronic Health Evaluation II, COPD = Chronic Obstructive Pulmonary Disease, ICU = Intensive Care Unit, MV = Mechanical Ventilation, SOFA = Sequential Organ Failure Assessment.}\)

\(\star\) Patients with MV follow.

### Table 5

The relationship of magnesium levels with COPD, 28-day mortality, and discharge from ICU.

| Hypomagnesemia | Normomagnesemia | Hypermagnesemia |
|----------------|-----------------|-----------------|
| \(n\) % | \(n\) % | \(n\) % | \(P\) (\(x^2\)) |
| COPD (+/-) | 59/26 | 69.4/30.6 | 149/70 | 68/32 | 14/11 | 56/44 | .432 |
| 28-day mortality (Yes/No) | 25/60 | 29.4/70.6 | 89/130 | 40.6/59.4 | 16/9 | 64/36 | .07 |
| Discharge (Transfer to inpatient service / ICU death) | 63/22 | 74.1/25.9 | 163/56 | 74.4/25.6 | 12/13 | 48/52 | .018 |

\(COPD = \text{Chronic Obstructive Pulmonary Disease, ICU = Intensive Care Unit.} \ x^2 = \text{Chi-Squared test.}\)

### Table 6

Relationship of hypomagnesemia, normomagnesemia, and hypermagnesemia with APACHE II, SOFA scores, CCI, length of hospital stay, length of stay in the ICU, length of MV, and potassium values.

| Hypomagnesemia | Normomagnesemia | Hypermagnesemia |
|----------------|-----------------|-----------------|
| Number | Mean Rank | Number | Mean Rank | Number | Mean Rank | \(x^2\)* | \(P\)** |
| Age (Years) | 85 | 145.42 | 219 | 174.17 | 25 | 151.28 | 6.1 | .46 |
| APACHE II | 85 | 154.65 | 219 | 164.13 | 25 | 207.76 | 6.0 | .48 |
| SOFA | 85 | 155.22 | 219 | 160.84 | 25 | 234.68 | 15.6 | .000 |
| CCI | 85 | 149.55 | 219 | 164.39 | 25 | 222.84 | 11.7 | .003 |
| Length of MV follow-up (days) (n=149) | 33 | 68.7 | 100 | 77.48 | 16 | 72.53 | 1.113 | .573 |
| Length of stay in the ICU (days) | 85 | 162.62 | 219 | 167.53 | 25 | 150.90 | 0.7 | .679 |
| Length of hospital stay (days) | 85 | 153.25 | 219 | 169.76 | 25 | 163.24 | 1.8 | .395 |
| Potassium (mEq/L) | 85 | 152.05 | 219 | 168.59 | 25 | 150.90 | 2.3 | .312 |

\(APACHE\ II = \text{Chronic Health Evaluation II, CCI = Charlson’s Comorbidity Index, ICU = Intensive Care Unit, MV = Mechanical Ventilation, SOFA = Sequential Organ Failure Assessment.}\)

\(\star\) Chi-Squared.

\(\star\) Kruskal-Wallis-H test.

### Table 7

Mean mortality prediction scores according to magnesium levels.

| Hypomagnesemia | Normomagnesemia | Hypermagnesemia |
|----------------|-----------------|-----------------|
| APACHE II | 21.42 | 22.16 | 26.64 |
| SOFA | 6.32 | 6.49 | 8.64 |
| CCI | 5.58 | 5.94 | 7.72 |

\(APACHE\ II = \text{Chronic Health Evaluation II, CCI = Charlson’s Comorbidity Index, SOFA = Sequential Organ Failure Assessment.}\)
groups are less than that of the normo-hypomagnesemia group, ICU mortality was found to be significantly higher in the former (P= .018). Additionally, these patients were in the group which did not have a COPD diagnosis and their APACHE II, SOFA, and CCI scores were higher.

Hypermagnesemia is an uncommon electrolyte disorder and its etiology is based on reduced renal excretion or increased magnesium intake in patients with acute or chronic renal failure. Increased magnesium absorption due to reduced gastrointestinal motility may be induced by inflammatory bowel diseases or the use of laxative treatments including anticholinergics, opioids, and magnesium. Moreover, hypermagnesemia can also develop due to a magnesium shift to serum from erythrocytes such as acidosis, rhabdomyolysis, and tumor lysis syndrome.[12] This study included only seven patients who received CRRT due to renal failure, and none of these patients had hypermagnesemia. Therefore, this study did not include a hypothesis on hypermagnesemia induced by renal excretion failure. The data regarding patients anamnesis of bowel diseases and motility disorders could not be obtained; however, frequently encountered bowel dysfunction in the patient group at high risk can be a determinant of hypermagnesemia. The effect of early enteral nutrition administration for patients in the ICU on outcomes is a well-known concept. Enteral nutrition given during routine care in the ICU can reduce magnesium abnormalities. Although this study found lower hypermagnesemia rates in the group which consisted mainly of COPD patients or those with other chronic hypoxic respiratory diseases, a magnesium shift from erythrocyte to serum and the related development of hypermagnesemia is possible in this group in which acidosis and hypoxia is commonly encountered. ARF is a clinical case that develops suddenly; however, besides newly diagnosed illnesses such as pneumonia and acute respiratory distress syndrome (ARDS), the underlying cause of ARF is associated with chronic respiratory or muscular disorder. COPD has continued to be one of the most common respiratory diseases that cause acute inflammation, infection related respiratory failure, and long and frequent hospital and ICU stays.[13] It has been shown that COPD is a systemic inflammatory illness that not only affects the respiratory system but also other organ systems, and has a significant effect on health care expenditures.[14,15] This study, which mostly included COPD patients, was designed based on the hypothesis that chronic systemic inflammatory stress is associated with low magnesium levels and affects the prognosis. However, contrary to this hypothesis, it was found that the patient group followed in the ICU was predominantly normomagnesemic, and the effect of magnesium levels of patients with COPD on mortality could not be confirmed. In line with this result, magnesium support and accepted magnesium cut-off values should be reevaluated for COPD patients whose stay in the hospital and ICU are frequent and long. However, when analyzing all patients without separating them according to the existence of COPD, it was found that a magnesium level higher than normal was significantly correlated with mortality. This can be associated with the extracellular increase of magnesium, one of the important intracellular cations in enzymatic reactions, during the catabolic process of the cells related to acute severe hypoxia. Similarly with this study, the fact that the mortality rate is higher in patients who have a diagnosis other than COPD and have higher CCI supports this hypothesis.

There are numerous studies on the effectivity of parameters such as APACHE II, SOFA, and CCI in predicting mortality of patients in the ICU, and these parameters continue to be up-to-date. In their study on patients with sepsis, Li et al[16] have found that particularly APACHE II and SOFA scores are effective in predicting 28-day mortality (P<.000 for each. AUC degrees for ROC analysis: APACHE II (0.893), SOFA (0.871)). Moreover, CCI is a commonly used test in the prediction of mortality. Yildiz et al[17] have found that the relationship between CCI and mortality was statistically significant. This study also found that the APACHE II, SOFA, and CCI was effective in predicting the 28-day mortality of patients in the ICU with ARF diagnosis. There are certain limitations in this study. This study is a monocenter and retrospective study. During this study, the magnesium levels were only measured during admission to the hospital and were not monitored during the follow-up process. Additionally, only the total serum magnesium level was measured and it was not separated into complex and ionized forms based on proteins and anions. However, repeated measures were not analyzed, since the aim of this study was to measure magnesium levels during admission to the ICU and evaluate the effect of the spot values on the mortality. Moreover, patients who were diagnosed with hypomagnesemia during the measurements were routinely given magnesium replacement. Patients renal clearance values and urine magnesium levels could not be obtained. More complex and well-designed studies which include a broader sample size, and technically separate different forms of magnesium should be carried out to confirm that hypermagnesemia is induced by cell lysis mechanism.

Author contributions

Conceptualization: Mustafa Özgür Cırık, Güler Eraslan Doğanay.
Data curation: Mustafa Özgür Cırık, Mukaddes Kılınc, Güler Eraslan Doğanay.
Formal analysis: Mustafa Özgür Cırık, Mukaddes Kılınc.
Investigation: Mukaddes Kılınc.
Methodology: Güler Eraslan Doğanay, Meriç Unver.
Project administration: Mustafa Özgür Cırık.
Resources: Güler Eraslan Doğanay, Meriç Unver.
Supervision: Murat Yıldız, Sema Avcı.
Visualization: Mukaddes Kılınc, Murat Yıldız.
Writing – original draft: Meriç Unver, Murat Yıldız.
Writing – review & editing: Sema Avcı.

References

[1] Zafar MSH, Wani JI, Karim R, et al. Significance of serum magnesium levels in critically ill-patients. Int J Appl Basic Med Res 2014;4: 34–7.
[2] Velissaris D, Karamouzos V, Pizarrakos C, et al. Hypomagnesemia in critically ill sepsis patients. J Clin Med Res 2015;7:911–8.
[3] Gonzalez W, Altieri PI, Alvarado S, et al. Magnesium: the forgotten electrolyte. Am J Clin Pathol 2014;102:616–22.
[4] Guerin C, Cousin C, Mignot F, et al. Serum and erythrocyte magnesium in critically ill patients. J Investig Med 1996;24:724–7.
[5] Karamanli H, Kizilirmak D, Akgedik R, et al. Serum levels of magnesium and their relationship with CRP in patients with OSA. Sleep Breath 2017;21:549–56.
[6] Ferre S, Li X, Adams-Huet B, et al. Low serum magnesium is associated with faster decline in kidney function: the Dallas Heart Study experience. J Investig Med 2019;67:987–94.
[7] Mak IT, Chmielinska JJ, Spurrey CF, et al. Combination ART-induced oxidative/nitrosative stress, neurogenic inflammation and cardiac...
dysfunction in HIV-1 transgenic (Tg) rats: protection by mg. Int J Mol Sci 2018;19.
[9] Oliveira ARS de, Cruz KJC, Severo JS, et al. Hypomagnesemia and its relation with chronic low-grade inflammation in obesity. Rev Assoc Med Bras 2017;63:156–63.
[10] Escuela MP, Guerra M, Anon JM, et al. Total and ionized serum magnesium in critically ill patients. Intensive Care Med 2005;31:151–6.
[11] Angkananard T, Anothaisintawee T, Eursiriwan S, et al. The association of serum magnesium and mortality outcomes in heart failure patients: a systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e5406.
[12] Cascella M, Vaqar S. Hypermagnesemia. [Updated 2020 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549811/
[13] Liao K-M, Chen Y-C, Cheng K-C, et al. Trends in intensive care unit admissions of COPD patients from 2003 to 2013 in Taiwan. Int J Chron Obstruct Pulmon Dis 2018;13:2007–12.
[14] Biondi NL, Samiratedu MM, Highsmith E, et al. The impact of interprofessional monitoring and education on the usage of systemic glucocorticoids in acute exacerbations of chronic obstructive pulmonary disease: a retrospective, medication use review. Cureus 2019;11:e6224.
[15] Felsenfeld AJ, Levine BS, Rodriguez M. Pathophysiology of calcium, phosphorus, and magnesium dysregulation in chronic kidney disease. Semin Dial 2015;28:564–77.
[16] Li Y, Li C. Comparison of simplified acute physiology score III and other scoring systems in prediction of 28-day prognosis in patients with severe sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2015;27:454–9.
[17] Yıldız A, Yigit A, Benli AR. The prognostic role of Charlson comorbidity index for critically ill elderly patients. Eur Res J 2020;6:67–72.